Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial

Journal of the National Cancer Institute

Volumn 88, Issue 21, 1996, Pages 1550-1559

  Omenn, Gilbert S ^a,b   Goodman, Gary E ^a   Thornquist, Mark D ^b   Balmes, John ^c   Cullen, Mark R ^d   Glass, Andrew ^e   Keogh, James P ^f   Meyskens Jr , Frank L ^g   Valanis, Barbara ^e   Williams Jr , James H ^g   Barnhart, Scott ^a   Cherniack, Martin G ^d   Brodkin, Carl Andrew ^a   Hammar, Samuel ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d YALE UNIVERSITY   (United States)

^e KAISER PERMANENTE   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; PLACEBO; RETINOL PALMITATE;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; SMOKING; STATISTICAL ANALYSIS; TREATMENT FAILURE;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; ASBESTOS; BETA CAROTENE; CARCINOGENS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING; VITAMIN A;

EID: 0038692733     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.21.1550     Document Type: Article

References (39)

1. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary β-carotene materially reduce human cancer rates? Nature 1981;290:201-9.
2. Greenwald P, Kramer BS, Weed DL, editors. Cancer prevention and control. New York: Marcel Dekker, 1995.
3. Lippman SM, Benner SE, Hong WK. Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis. Cancer Res 1994;54(7 Suppl):2025s-2028s.
4. Omenn GS, Goodman GE, Thornquist MD, Rosenstock L, Barnhart S, Gylys-Colwell I, et al. The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with asbestos-exposed workers. Cancer Epidemiol Biomarkers Prev 1993;2:381-7.
5. Goodman GE, Omenn GS, Thornquist MD, Lund B, Metch B, Gylys-Colwell I. The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with cigarette smokers. Cancer Epidemiol Biomarkers Prev 1993;2:389-96.
6. Thornquist MD, Omenn GS, Goodman GE, Grizzle JE, Rosenstock L, Barnhart S, et al. Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET). Controlled Clin Trials 1993;14:308-24.
7. Omenn GS, Goodman GE, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, et al. The β-Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res 1994;54(7 Suppl):2038s-2043s.
8. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease [see comment citation in Medline]. N Engl J Med 1996;334:1150-5.
9. van Vliet T, van Vlissingen MF, van Schaik F, van den Berg H. β-Carotene absorption and cleavage in rats is affected by the vitamin A concentration of the diet. J Nutr 1996;125:499-508.
10. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, et al. α-Tocopherol and α-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88:000-00.
11. US Department of Health and Human Services. International Classification of Diseases, 9th Revision, Clinical Modification. 4th revised edition. Salt Lake City (UT): Medicode Publications, 1994.
12. Yesner R. Classification of lung-cancer histology [letter]. N Engl J Med 1985;12:652-3.
13. Dail DH, Hammar SP, editors. Pulmonary pathology. New York: Springer-Verlag, 1988:1029-94.
14. Loy TS, Darkow GV, Quesenberry JT. Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas. Am J Surg Pathol 1995;19:173-82.
15. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
16. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985;41:361-72.
17. Bishop YM, Fienberg SE, Holland PW. Discrete multivariate analysis: theory and practice. Cambridge (MA): MIT Press, 1975.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
19. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group [see comment citations in Medline]. N Engl J Med 1994;330:1029-35.
20. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease [see comment citation in Medline]. N Engl J Med 1996;334:1145-9.
21. Buring JE, Hennekens CH. The Women's Health Study: summary of the study design. J Myocardial Ischemia 1992;4:27-9.
22. Manson JE, Gaziano JM, Spelsberg A, Ridker PM, Cook NR, Buring JE, et al. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group [see comment citation in Medline]. Ann Epidemiol 1995; 5:261-9.
23. Goodman GE, Metch BJ, Omenn GS. The effect of long-term β-carotene and vitamin A administration on serum concentrations of α-tocopherol. Cancer Epidemiol Biomarkers Prev 1994;3:429-32.
24. Xu MJ, Plezia PM, Alberts DS, Emerson SS, Peng YM, Sayers SM, et al. Reduction in plasma or skin α-tocopherol concentration with long-term oral administration of β-carotene in humans and mice. J Natl Cancer Inst 1992;84:1559-65.
25. Nierenberg DW, Stukel TA, Mott LA, Greenberg ER. Steady-state serum concentration of α-tocopherol not altered by supplementation with oral β-carotene. The Polyp Prevention Study 1 Group. J Natl Cancer Inst 1994;86:117-20.
26. McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kummet TD, Greenberg SD. β-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 1995;62(6 Suppl):1431S-1438S.
27. Gaziano JM, Johnson EJ, Russell RM, Manson JE, Stampfer MJ, Ridker PM, et al. Discrimination in absorption or transport of beta-carotene isomers after oral supplementation with either all-trans or 9-cis-beta-carotene. Am J Clin Nutr 1995;61:1248-52.
28. Krinsky NI. Actions of carotenoids in biological systems. Annu Rev Nutr 1993;13:561-87.
29. Eiserich JP, van der Vliet A, Handelman GJ, Halliwell B, Cross CE. Dietary antioxidants and cigarette smoke-induced biomolecular damage: a complex interaction. Am J Clin Nutr 1995;62(6 Suppl):1490S-1500S.
30. Burton GW, Ingold KU. β-Carotene: an unusual type of lipid antioxidanl. Science 1984;224:569-73.
31. Handelman GJ, Packer L, Cross CE. Destruction of tocopherols, carotenoids, and retinol in human plasma by cigarette smoke. Am J Clin Nutr 1996;63:559-65.
32. Kennedy TA, Liebler DC. Peroxyl radical oxidation of β-carotene: formation of β-carotene epoxides. Chem Res Toxicol 1991;4:290-5.
33. Ozhogina OA, Kasaikina OT. β-Carotene as an interceptor of free radicals. Free Radic Biol Med 1995;19:575-81.
34. Yamauchi R, Miyake N, Inoue H, Kato K. Products formed by peroxyl radical oxidation of β-carotene. J Agric Food Chem 1995;41:708-13.
35. Khan AU, Wilson T. Reactive oxygen species as cellular messengers. Chem Biol 1995;2:437-45.
36. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake [see comment citations in Medline]. N Engl J Med 1995;333:1369-73.
37. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as cause of oxidative damage. N Engl J Med 1995; 332:1198-203.
38. Commission on Risk Assessment and Risk Management. Risk assessment and risk management in regulatory decision-making. Draft report to the Congress and the President. Washington (DC): Risk Commission, June 1996; Section 6.3.3, page 132.
39. Rom WN, editor. Environmental and occupational medicine. 2nd ed. Boston: Little, Brown & Co., 1992.